Patented adult stem cells of Mesoblast which were injected by catheter into damaged heart muscles of sheep after they suffered a heart attack during preclinical trials have produced positive results. Texas Heart Institute conducted the trials. The clinical trials had been conducted in order to decide on the safety of the stem cells in an applicable protocol by using catheters for implanting cells in the damaged heart muscles after an attack and opening up of the blocked artery. Fifteen sheep were used during the trials. Up till now a number of large animal studies have been conducted by the company so that the data could be submitted to the FDA for approval. These results would be now used for supporting the company’s FDA submissions for second phase of the trials.